All enrolled individuals who obtained at the least just one dose of zosuquidar or placebo during induction were monitored with the incidence of adverse functions (439 sufferers, 219 on zosuquidar and 210 on placebo). The most common adverse events were being relevant to the period of extended and important myelosuppression https://actonf444tdo6.wiki-promo.com/user